Cita APA

Munir, T., Moreno, C., Owen, C., Follows, G., Benjamini, O., Janssens, A., . . . Kater, A. P. (2023). Impact of Minimal Residual Disease on Progression-Free Survival Outcomes after Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study.

Citación estilo Chicago

Munir, Talha|||0000-0002-2901-0769, et al. Impact of Minimal Residual Disease On Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study. 2023.

Cita MLA

Munir, Talha|||0000-0002-2901-0769, et al. Impact of Minimal Residual Disease On Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study. 2023.